Early Access — free while we kick the tires
EdgarHawk

German Christopher Paul

Corporate Controller & CAO

Officer
1 filing analyzed · 1 company · Latest 2026-03-06

Companies

Company Buys Sells Direction
RHYTHM PHARMACEUTICALS, INC. RYTM 0 2 Net selling

Activity

March 2026
high
Sell
5,614 shares
$502,790
Significance 7/10

Corporate Controller of RYTM sold 5,614 shares (97.2% of holdings) at $89.56; stock now -20.5% from 52-week high despite +45.8% revenue growth.

Corporate Controller Christopher Paul executed a large reduction of his stake, selling 5,614 shares and leaving just 160 shares post-transaction. The timing is notable given the company's recent price decline of -13.4% over 30 days and -10.6% over 90 days, bringing the stock to -20.5% below its 52-week high of $117.62. The company reported strong annual revenue growth of +45.8% and current-quarter revenue of $51.3M, but remains unprofitable with a full-year net income of $-52.9M and latest quarterly losses of $-52.9M. This near-complete liquidation by a C-suite financial officer—retaining only 160 shares of a $6.4B market-cap company—during a period of stock weakness and persistent operating losses warrants close monitoring of the company's financial trajectory and cash position.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access